CDCharles Drescher

Charles Drescher

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles Drescher has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Nicole Urban

    Translational Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

    4 shared publications
  • M. Robyn Andersen

    Translational Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

    3 shared publications
  • Nicole Urban

    Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    3 shared publications
  • Jason Thorpe

    Translational Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

    2 shared publications
  • Martin W. McIntosh

    Charles W. Drescher, Jason Thorpe, Kathy O'Briant, Garnet L. Anderson, Nicole Urban, and Martin W. McIntosh, Fred Hutchinson Cancer Research Center; Chirag Shah, Pacific Gynecology Specialists, Seattle, WA; and Christine D. Berg, National Cancer Institute, Bethesda, MD

    2 shared publications
  • Sarah Hawley

    Translational Outcomes Research, Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington

    2 shared publications

Latest Publications

  • Open Access

    The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial

    by Charles W. Drescher, J. David Beatty, Robert Resta, M. Robyn Andersen, Kate Watabayashi, Jason Thorpe, Sarah Hawley, Hannah Purkey, Jessica Chubak, Nancy Hanson, et al.

    BACKGROUND: Guidelines recommend genetic counseling and testing for women who have a pedigree suggestive of an inherited susceptibility for ovarian cancer. The authors evaluated the effect of referral to genetic counseling on genetic testing and prophylactic oophorectomy in a randomized controlled trial.METHODS: Data from an electronic mammography reporting system identified 12,919 women with a pedigree that included breast cancer, of whom 625 were identified who had a high risk for inherited susceptibility to ovarian cancer using a risk‐assessment questionnaire. Of these, 458 women provided informed consent and were randomized 1:1 to intervention consisting of a genetic counseling referral (n = 228) or standard clinical care (n = 230).RESULTS: Participants were predominantly aged 45 to 65 years, and 30% and 20% reported a personal history of breast cancer or a family history of ovarian cancer, respectively. Eighty‐five percent of women in the intervention group participated in a genetic counseling session. Genetic testing was reported by 74 (33%) and 20 (9%) women in the intervention and control arms (P < .005), respectively. Five women in the intervention arm and 2 in the control arm were identified as germline mutation carriers. Ten women in the intervention arm and 3 in the control arm underwent prophylactic bilateral salpingo‐oophorectomy (P < .05).CONCLUSIONS: Routine referral of women at high risk for ovarian cancer to genetic counseling promotes genetic testing and prophylactic surgery. The findings from the current randomized controlled trial demonstrate the value of implementing strategies that target women at high risk for ovarian cancer to ensure they are offered access to recommended care. CA Cancer J Clin 2016. © 2016 American Cancer Society, Inc. Cancer 2016;122:3509–3518. © 2016 American Cancer Society


  • Longitudinal Screening Algorithm That Incorporates Change Over Time in CA125 Levels Identifies Ovarian Cancer Earlier Than a Single-Threshold Rule

    by Charles W. Drescher, Chirag Shah, Jason Thorpe, Kathy O'BRiant, Garnet L. Anderson, Christine D. Berg, Nicole Urban, Martin W. McIntosh

    Purpose: Longitudinal algorithms incorporate change over time in biomarker levels to individualize screening decision rules. Compared with a single-threshold (ST) rule, smaller deviations from baseline biomarker levels are required to signal disease. We demonstrated improvement in ovarian cancer early detection by using a longitudinal algorithm to monitor annual CA125 levels. Patients and Methods: We retrospectively evaluated serial preclinical serum CA125 values measured annually in 44 incident ovarian cancer cases identified from participants in the PLCO (Prostate Lung Colorectal and Ovarian) Cancer Screening Trial to determine how frequently and to what extent the parametric empirical Bayes (PEB) longitudinal screening algorithm identifies ovarian cancer earlier than an ST rule. Results: The PEB algorithm detected ovarian cancer earlier than an ST rule in a substantial proportion of cases. At 99% specificity, which corresponded to the ST-rule CA125 cutoff ≥ 35 U/mL that was used in the PLCO trial, 20% of cases were identified earlier by using the PEB algorithm. Among these cases, the PEB signaled abnormal CA125 values, on average, 10 months earlier and at a CA125 concentration 42% lower (20 U/mL) than the ST-rule cutoff. The proportion of cases detected earlier by the PEB algorithm and the earliness of detection increased as the specificity of the screening rule was reduced. Conclusion: The PEB longitudinal algorithm identifies ovarian cancer earlier and at lower biomarker concentrations than an ST screening algorithm adjusted to the same specificity. Longitudinal biomarker assessment by using the PEB algorithm may have application for screening other solid tumors in which biomarkers are available.


  • Impact of Screening Test Performance and Cost on Mortality Reduction and Cost-effectiveness of Multimodal Ovarian Cancer Screening

    by Charles W. Drescher, Sarah Hawley, Jason D. Thorpe, Simone Marticke, Martin McIntosh, Sanjiv S. Gambhir, Nicole Urban

    Ongoing ovarian cancer screening trials are investigating the efficacy of a two-step screening strategy using currently available blood and imaging tests [CA125 and transvaginal sonography (TVS)]. Concurrently, efforts to develop new biomarkers and imaging tests seek to improve screening performance beyond its current limits. This study estimates the mortality reduction, years of life saved, and cost-effectiveness achievable by annual multimodal screening using increasing CA125 to select women for TVS, and predicts improvements achievable by replacing currently available screening tests with hypothetical counterparts with better performance characteristics. An existing stochastic microsimulation model is refined and used to screen a virtual cohort of 1 million women from ages 45 to 85 years. Each woman is assigned a detailed disease course and screening results timeline. The preclinical behavior of CA125 and TVS is simulated using empirical data derived from clinical trials. Simulations in which the disease incidence and performance characteristics of the screening tests are independently varied are conducted to evaluate the impact of these factors on overall screening performance and costs. Our results show that when applied to women at average risk, annual screening using increasing CA125 to select women for TVS achieves modest mortality reduction (∼13%) and meets currently accepted cost-effectiveness guidelines. Screening outcomes are relatively insensitive to second-line test performance and costs. Identification of a first-line test that does substantially better than CA125 and has similar costs is required for screening to reduce ovarian mortality by at least 25% and be reasonably cost-effective. Cancer Prev Res; 5(8); 1015–24. ©2012 AACR.


  • Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling

    by Gaia Pocobelli, Jessica Chubak, Nancy Hanson, Charles Drescher, Robert Resta, Nicole Urban, Diana S.M. Buist


  • Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125

    by Michèl Schummer, Charles Drescher, Robin Forrest, Shirley Gough, Jason Thorpe, Ingegerd Hellström, Karl Erik Hellström, Nicole Urban


  • Open Access

    Current and Future Developments in Screening for Ovarian Cancer

    by Nicole Urban, Charles Drescher

    Over 90% of women diagnosed with localized ovarian cancer survive at least 5 years, but because the disease is often advanced at diagnosis, only half of patients survive that long. Currently, screening is only recommended for women with a strong family history of the disease, for whom prophylactic surgery is appropriate once childbearing is complete. Screening is not recommended for the general population since currently available screening tests seldom detect curable tumors, and often lead to unnecessary surgery. New markers are under investigation that may signal disease earlier and be useful in a marker panel to select women for imaging and/or surgery. A clinical challenge is that definitive diagnosis requires major abdominal surgery, and screening tests often detect benign ovarian conditions. A challenge for translational research in biomarkers for early detection is that access is needed to preclinical blood samples, obtained some months prior to diagnosis, in order to determine if candidate markers can detect disease prior to onset of symptoms.


  • Open Access

    Compliance of Average- and Intermediate-Risk Women to Semiannual Ovarian Cancer Screening

    by Charles W. Drescher, Judy Nelson, Sue Peacock, M. Robyn Andersen, Martin W. McIntosh, Nicole Urban

    Objective: To report rates of compliance with an ovarian cancer screening protocol using serum CA125 and transvaginal sonography (TVS), performed semiannually on an alternating schedule, among participants at average or intermediate risk for developing ovarian cancer. Methods: Two hundred ninety-two women at average or intermediate risk for developing ovarian cancer were randomly assigned to arms of a controlled clinical trial in which they received ovarian cancer screening consisting of serum CA125 alternating with TVS performed semiannually over 18 months, either alone or in combination with ovarian cancer risk education. A computerized tracking system generated screening appointment reminder letters and monitored adherence to scheduled screening. Participants overdue for scheduled screens received follow-up telephone calls consisting of up to four reminder messages left at 1-week intervals, and one to two interim attempts to reach participants between messages. The compliance rate for each screen was calculated as a ratio of the number of participants successfully completing the screen relative to the number expected to attend. Compliance rate by screen was: screen 1 (CA125) (97.3%), screen 2 (TVS) (82.5%), screen 3 (CA125) (79.0%), and screen 4 (TVS) (64.5%). One hundred seventy-two women completed all four screens and were classified as adherent to the screening protocol. Analysis by screening modality suggests that participants were more compliant to screens involving CA125. Age, educational background, distance from screening center, personal or family history of cancer, perceived risk of ovarian cancer, pre-enrollment ovarian cancer screening behavior, receiving an abnormal screen test result, and participation in ovarian cancer risk education sessions were not associated with adherence to the screening protocol or compliance to any of the screens. Conclusions: Despite extensive follow-up, compliance of average- and intermediate-risk women to an ovarian cancer screening protocol requiring semiannual screening diminishes rapidly. We propose that a semiannual ovarian cancer screening protocol, particularly one including TVS, may be too intensive for use in this population.


  • Reported ovarian cancer screening among a population-based sample in Washington state

    by C Drescher, S K Holt, M R Andersen, G Anderson, N Urban

    To assess the prevalence of reported ovarian cancer screening among a population-based sample of women from Washington state and identify factors that influence the decision to be screened. A population-based sample of 6749 women aged 54-84 years, living in 40 predominately rural communities in Washington state, was surveyed about their utilization of ultrasonography and CA 125 for ovarian cancer screening. We also assessed relevant demographic, family history, psychosocial, and health behavior variables. After exclusions, data from 4938 respondents were available. Two percent (n = 96) reported having been screened. Multiple logistic regression identified ovarian cancer worry, contact with an obstetrician-gynecologist, and family history of ovarian cancer as independently associated with screening. Based on self-reported family histories, 27 women had pedigrees consistent with high risk of ovarian cancer, but none of those women reported having been screened. Ovarian cancer screening is rare. Women at high risk of it might not be getting recommended screening.


  • Reported Ovarian Cancer Screening Among a Population-Based Sample in Washington State

    by Charles Drescher, Sarah K. Holt, M. Robyn Andersen, Garnet Anderson, NICOLE ScD URBAN

    Objective To assess the prevalence of reported ovarian cancer screening among a population-based sample of women from Washington state and identify factors that influence the decision to be screened. Methods A population-based sample of 6749 women aged 54–84 years, living in 40 predominately rural communities in Washington state, was surveyed about their utilization of ultrasonography and CA 125 for ovarian cancer screening. We also assessed relevant demographic, family history, psychosocial, and health behavior variables. Results After exclusions, data from 4938 respondents were available. Two percent (n = 96) reported having been screened. Multiple logistic regression identified ovarian cancer worry, contact with an obstetrician-gynecologist, and family history of ovarian cancer as independently associated with screening. Based on self-reported family histories, 27 women had pedigrees consistent with high risk of ovarian cancer, but none of those women reported having been screened. Conclusion Ovarian cancer screening is rare. Women at high risk of it might not be getting recommended screening.